Ascendis Pharma A/S (NASDAQ:ASND) Receives $191.57 Consensus Price Target from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus recommendation of “Moderate Buy” by the fourteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $191.57.

Several research analysts have recently commented on ASND shares. TD Cowen cut their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Wedbush reissued an “outperform” rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th.

Ascendis Pharma A/S Stock Down 3.3 %

Ascendis Pharma A/S stock opened at $120.87 on Monday. The stock has a market cap of $7.34 billion, a price-to-earnings ratio of -14.96 and a beta of 0.64. The business has a 50-day simple moving average of $132.60 and a 200 day simple moving average of $132.47. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP raised its stake in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Janus Henderson Group PLC raised its position in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after buying an additional 155,971 shares during the period. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $60,000. Finally, ARS Investment Partners LLC increased its stake in shares of Ascendis Pharma A/S by 0.9% during the fourth quarter. ARS Investment Partners LLC now owns 265,480 shares of the biotechnology company’s stock valued at $36,549,000 after buying an additional 2,369 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.